However, no previous study has validated KL-6 in distinguishing TR-ILD from pneumonia or non-ILD events at the onset of adverse events similar to ILD after cancer treatment19, which can be encountered in actual clinical practice. This evidence concerns the gene MUC1 and pneumonia.